Published in Nat Biotechnol on September 01, 2005
Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A (2012) 2.13
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs (2010) 1.86
Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging (2009) 1.62
A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J Pharmacol Exp Ther (2006) 1.53
Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun (2006) 1.38
Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat Biotechnol (2009) 1.34
Engineering the variable region of therapeutic IgG antibodies. MAbs (2011) 1.33
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A (2014) 1.32
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. MAbs (2009) 1.20
Monoclonal antibody therapies against anthrax. Toxins (Basel) (2011) 1.19
Clinical development of anti-RANKL therapy. Arthritis Res Ther (2007) 1.17
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A (2014) 1.15
Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A (2008) 1.14
Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res (2008) 1.13
The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J Pharmacol Exp Ther (2008) 1.12
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol (2009) 1.11
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One (2010) 1.08
Characterization of a recombinant humanized anti-cocaine monoclonal antibody and its Fab fragment. Hum Vaccin Immunother (2015) 1.05
Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev (2012) 1.05
Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc Natl Acad Sci U S A (2011) 0.98
Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther (2009) 0.97
Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother (2012) 0.95
A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats. Drug Metab Dispos (2014) 0.93
Current ADC Linker Chemistry. Pharm Res (2015) 0.92
Mining human antibody repertoires. MAbs (2010) 0.92
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol (2016) 0.91
Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines. Viruses (2015) 0.91
Harnessing gene conversion in chicken B cells to create a human antibody sequence repertoire. PLoS One (2013) 0.91
The construction of transgenic and gene knockout/knockin mouse models of human disease. Transgenic Res (2011) 0.91
Characterization of the rabbit neonatal Fc receptor (FcRn) and analyzing the immunophenotype of the transgenic rabbits that overexpresses FcRn. PLoS One (2012) 0.90
The smart targeting of nanoparticles. Curr Pharm Des (2013) 0.89
Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther (2008) 0.89
High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region. J Immunol (2013) 0.88
Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs (2012) 0.87
Human monoclonal antibodies broadly neutralizing against influenza B virus. PLoS Pathog (2013) 0.86
Emerging antigenic variants at the antigenic site Sb in pandemic A(H1N1)2009 influenza virus in Japan detected by a human monoclonal antibody. PLoS One (2013) 0.86
Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell (2010) 0.84
Novel human antibody therapeutics: the age of the Umabs. Biotechnol J (2008) 0.84
Antibody therapy for Ebola: is the tide turning around? Hum Vaccin Immunother (2014) 0.84
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol (2011) 0.83
High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation. PLoS One (2012) 0.83
Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology. Int J Cell Biol (2013) 0.83
Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody. Immunotherapy (2012) 0.83
Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells. BMC Biotechnol (2008) 0.82
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. MAbs (2010) 0.81
Transgenic rabbits that overexpress the neonatal Fc receptor (FcRn) generate higher quantities and improved qualities of anti-thymocyte globulin (ATG). PLoS One (2013) 0.80
Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential. Toxins (Basel) (2014) 0.80
A Diverse Repertoire of Human Immunoglobulin Variable Genes in a Chicken B Cell Line is Generated by Both Gene Conversion and Somatic Hypermutation. Front Immunol (2015) 0.79
NANOSCALE SELF-ASSEMBLY FOR DELIVERY OF THERAPEUTICS AND IMAGING AGENTS. Technol Innov (2011) 0.78
Engineering therapeutic antibodies targeting G-protein-coupled receptors. Exp Mol Med (2016) 0.78
Identification of human monoclonal antibodies specific for human SOD1 recognizing distinct epitopes and forms of SOD1. PLoS One (2013) 0.78
Development of scoring functions for antibody sequence assessment and optimization. PLoS One (2013) 0.78
The transgenic cloned pig population with integrated and controllable GH expression that has higher feed efficiency and meat production. Sci Rep (2015) 0.78
A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer. MAbs (2014) 0.78
Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther (2016) 0.78
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vasc Health Risk Manag (2016) 0.77
Targeting membrane proteins for antibody discovery using phage display. Sci Rep (2016) 0.77
An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification. MAbs (2012) 0.76
Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential. MAbs (2014) 0.76
Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors. Clin Cancer Drugs (2016) 0.76
Species-Specific Chromosome Engineering Greatly Improves Fully Human Polyclonal Antibody Production Profile in Cattle. PLoS One (2015) 0.76
Antigen-specific monoclonal antibodies isolated from B cells expressing constitutively active STAT5. PLoS One (2011) 0.76
Update on biological therapeutics for asthma. World Allergy Organ J (2010) 0.76
Recent advances in the generation of human monoclonal antibody. Cytotechnology (2007) 0.76
Intellectual property issues of immune checkpoint inhibitors. MAbs (2015) 0.75
A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors. MAbs (2016) 0.75
Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther (2017) 0.75
Antibody humanization by molecular dynamics simulations-in-silico guided selection of critical backmutations. J Mol Recognit (2016) 0.75
New engineered antibodies against prions. Bioengineered (2013) 0.75
Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering. Sci Rep (2017) 0.75